TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.00200nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0400nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.150nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.220nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.230nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.25nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.340nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.600nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.780nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.800nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 2.5nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 3.20nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 4.20nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 60.8nMAssay Description:In a typical experiment the PDE10 inhibitory activity of the compounds of the present invention was determined in accordance with the following exper...More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of ADP-mediated platelet aggregation in human gel-filtered plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 19nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 23nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 25nMAssay Description:Inhibition of ADP-mediated platelet aggregation in human gel-filtered plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 27nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 32nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 36nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 410nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 500nMAssay Description:The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)More data for this Ligand-Target Pair
Affinity DataIC50: 530nMAssay Description:Inhibition of ADP-mediated platelet aggregation in human gel-filtered plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 1.10E+3nMAssay Description:Inhibition of ADP-mediated platelet aggregation in human gel-filtered plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 1.60E+3nMAssay Description:Inhibition of ADP-mediated platelet aggregation in human gel-filtered plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 2.00E+3nMAssay Description:Inhibition of ADP-mediated platelet aggregation in human gel-filtered plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of ADP-mediated platelet aggregation in human gel-filtered plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 2.60E+4nMAssay Description:Inhibition of ADP-mediated platelet aggregation in human gel-filtered plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+5nMAssay Description:Inhibition of ADP-mediated platelet aggregation in human gel-filtered plateletsMore data for this Ligand-Target Pair
Affinity DataKd: 0.150nMAssay Description:Equilibrium dissociation constant was measured from displacement of L-762,745 from Fibrinogen receptor of human platelets by flow cytometryMore data for this Ligand-Target Pair
Affinity DataKd: 22nMAssay Description:Equilibrium dissociation constant was measured from displacement of L-762,745 from Fibrinogen receptor of human platelets by flow cytometryMore data for this Ligand-Target Pair
Affinity DataKd: 0.150nMAssay Description:Equilibrium dissociation constant was measured from displacement of L-762,745 from Fibrinogen receptor of human platelets by flow cytometryMore data for this Ligand-Target Pair
Affinity DataKd: 1.20nMAssay Description:Displacement of L-762,745 from Fibrinogen Receptor of human platelets by flow cytometryMore data for this Ligand-Target Pair
Affinity DataKd: 0.0700nMAssay Description:Equilibrium dissociation constant was measured from displacement of L-762,745 from Fibrinogen receptor of human platelets by flow cytometryMore data for this Ligand-Target Pair